These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

511 related articles for article (PubMed ID: 12166927)

  • 1. 6alpha-ethyl-chenodeoxycholic acid (6-ECDCA), a potent and selective FXR agonist endowed with anticholestatic activity.
    Pellicciari R; Fiorucci S; Camaioni E; Clerici C; Costantino G; Maloney PR; Morelli A; Parks DJ; Willson TM
    J Med Chem; 2002 Aug; 45(17):3569-72. PubMed ID: 12166927
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Protective effects of 6-ethyl chenodeoxycholic acid, a farnesoid X receptor ligand, in estrogen-induced cholestasis.
    Fiorucci S; Clerici C; Antonelli E; Orlandi S; Goodwin B; Sadeghpour BM; Sabatino G; Russo G; Castellani D; Willson TM; Pruzanski M; Pellicciari R; Morelli A
    J Pharmacol Exp Ther; 2005 May; 313(2):604-12. PubMed ID: 15644430
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bile acid derivatives as ligands of the farnesoid X receptor. Synthesis, evaluation, and structure-activity relationship of a series of body and side chain modified analogues of chenodeoxycholic acid.
    Pellicciari R; Costantino G; Camaioni E; Sadeghpour BM; Entrena A; Willson TM; Fiorucci S; Clerici C; Gioiello A
    J Med Chem; 2004 Aug; 47(18):4559-69. PubMed ID: 15317466
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cross-talk between farnesoid-X-receptor (FXR) and peroxisome proliferator-activated receptor gamma contributes to the antifibrotic activity of FXR ligands in rodent models of liver cirrhosis.
    Fiorucci S; Rizzo G; Antonelli E; Renga B; Mencarelli A; Riccardi L; Morelli A; Pruzanski M; Pellicciari R
    J Pharmacol Exp Ther; 2005 Oct; 315(1):58-68. PubMed ID: 15980055
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Progress in the ligands and their complex structures of farnesoid X receptor].
    Li WH; Fu J; Zheng MY; Liu GX; Tang Y
    Yao Xue Xue Bao; 2012 Jun; 47(6):704-15. PubMed ID: 22919716
    [TBL] [Abstract][Full Text] [Related]  

  • 6. T0901317 is a dual LXR/FXR agonist.
    Houck KA; Borchert KM; Hepler CD; Thomas JS; Bramlett KS; Michael LF; Burris TP
    Mol Genet Metab; 2004; 83(1-2):184-7. PubMed ID: 15464433
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An improved synthesis of 6α-ethylchenodeoxycholic acid (6ECDCA), a potent and selective agonist for the Farnesoid X Receptor (FXR).
    Yu D; Mattern DL; Forman BM
    Steroids; 2012 Nov; 77(13):1335-8. PubMed ID: 22999992
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The farnesoid X receptor: a novel drug target?
    Claudel T; Sturm E; Kuipers F; Staels B
    Expert Opin Investig Drugs; 2004 Sep; 13(9):1135-48. PubMed ID: 15330745
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Farnesoid x receptor ligands inhibit vascular smooth muscle cell inflammation and migration.
    Li YT; Swales KE; Thomas GJ; Warner TD; Bishop-Bailey D
    Arterioscler Thromb Vasc Biol; 2007 Dec; 27(12):2606-11. PubMed ID: 18029909
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Binding mode of 6ECDCA, a potent bile acid agonist of the farnesoid X receptor (FXR).
    Costantino G; Macchiarulo A; Entrena-Guadix A; Camaioni E; Pellicciari R
    Bioorg Med Chem Lett; 2003 Jun; 13(11):1865-8. PubMed ID: 12749886
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Obeticholic acid, a synthetic bile acid agonist of the farnesoid X receptor, attenuates experimental autoimmune encephalomyelitis.
    Ho PP; Steinman L
    Proc Natl Acad Sci U S A; 2016 Feb; 113(6):1600-5. PubMed ID: 26811456
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Back door modulation of the farnesoid X receptor: design, synthesis, and biological evaluation of a series of side chain modified chenodeoxycholic acid derivatives.
    Pellicciari R; Gioiello A; Costantino G; Sadeghpour BM; Rizzo G; Meyer U; Parks DJ; Entrena-Guadix A; Fiorucci S
    J Med Chem; 2006 Jul; 49(14):4208-15. PubMed ID: 16821780
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Structure-activity relationship of bile acids and bile acid analogs in regard to FXR activation.
    Fujino T; Une M; Imanaka T; Inoue K; Nishimaki-Mogami T
    J Lipid Res; 2004 Jan; 45(1):132-8. PubMed ID: 13130122
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The nuclear receptor SHP mediates inhibition of hepatic stellate cells by FXR and protects against liver fibrosis.
    Fiorucci S; Antonelli E; Rizzo G; Renga B; Mencarelli A; Riccardi L; Orlandi S; Pellicciari R; Morelli A
    Gastroenterology; 2004 Nov; 127(5):1497-512. PubMed ID: 15521018
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery and optimization of 1,3,4-trisubstituted-pyrazolone derivatives as novel, potent, and nonsteroidal farnesoid X receptor (FXR) selective antagonists.
    Huang H; Yu Y; Gao Z; Zhang Y; Li C; Xu X; Jin H; Yan W; Ma R; Zhu J; Shen X; Jiang H; Chen L; Li J
    J Med Chem; 2012 Aug; 55(16):7037-53. PubMed ID: 22862148
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bile acids induce the expression of the human peroxisome proliferator-activated receptor alpha gene via activation of the farnesoid X receptor.
    Pineda Torra I; Claudel T; Duval C; Kosykh V; Fruchart JC; Staels B
    Mol Endocrinol; 2003 Feb; 17(2):259-72. PubMed ID: 12554753
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Conformationally constrained farnesoid X receptor (FXR) agonists: Naphthoic acid-based analogs of GW 4064.
    Akwabi-Ameyaw A; Bass JY; Caldwell RD; Caravella JA; Chen L; Creech KL; Deaton DN; Jones SA; Kaldor I; Liu Y; Madauss KP; Marr HB; McFadyen RB; Miller AB; Navas F; Parks DJ; Spearing PK; Todd D; Williams SP; Wisely GB
    Bioorg Med Chem Lett; 2008 Aug; 18(15):4339-43. PubMed ID: 18621523
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Farnesoid X receptor agonist for the treatment of liver and metabolic disorders: focus on 6-ethyl-CDCA.
    Fiorucci S; Cipriani S; Mencarelli A; Baldelli F; Bifulco G; Zampella A
    Mini Rev Med Chem; 2011 Aug; 11(9):753-62. PubMed ID: 21707532
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The ileum-liver Farnesoid X Receptor signaling axis mediates the compensatory mechanism of 17α-ethynylestradiol-induced cholestasis via increasing hepatic biosynthesis of chenodeoxycholic acids in rats.
    Zhang F; Xi L; Duan Y; Qin H; Wei M; Wu Y; Li B; Zhou Y; Wu X
    Eur J Pharm Sci; 2018 Oct; 123():404-415. PubMed ID: 30077711
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Conicasterol E, a small heterodimer partner sparing farnesoid X receptor modulator endowed with a pregnane X receptor agonistic activity, from the marine sponge Theonella swinhoei.
    Sepe V; Ummarino R; D'Auria MV; Chini MG; Bifulco G; Renga B; D'Amore C; Debitus C; Fiorucci S; Zampella A
    J Med Chem; 2012 Jan; 55(1):84-93. PubMed ID: 22126372
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.